Upadacitinib Combined with NB-UVB for Non-Segmental Vitiligo: A Single-Center Prospective Study

Clicks: 16
ID: 332143
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #144 of 238 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 238 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Vitiligo is a chronic autoimmune depigmenting disorder with limited therapeutic options for patients with active and refractory disease. Janus kinase (JAK) inhibitors have emerged as promising treatments, and combination therapy with phototherapy may further enhance repigmentation. Objectives To evaluate the efficacy and safety of oral upadacitinib combined with narrowband ultraviolet B (NB-UVB) phototherapy in patients with active non-segmental vitiligo. Methods In this prospective cohort study, adults with active non-segmental vitiligo and inadequate response to prior therapies received either oral upadacitinib (15 mg once daily) combined with NB-UVB phototherapy or NB-UVB alone for 12 weeks. The primary endpoint was achievement of ≥50% improvement in total Vitiligo Area Scoring Index (T-VASI50) at week 12. Secondary endpoints included changes in T-VASI, facial VASI (F-VASI), Vitiligo Extent Score (VES), and disease activity and improvement scores (VDAS/VDIS). Safety was assessed throughout the study. Results A total of 38 patients were included, with 19 patients in each treatment group. At week 12, 47.4% of patients in the combination group achieved T-VASI50, compared with 5.3% in the NB-UVB monotherapy group (P = 0.0078). The combination group showed significantly greater mean percentage improvements in T-VASI (49.1%±20.3% vs 18.7%±14.3%, P < 0.01) and VES (44.6%±20.1% vs 18.6%±13.8%, P < 0.01). Superior responses were observed in truncal and non-acral extremity lesions, whereas facial outcomes did not differ significantly between groups. All adverse events were mild, and no serious adverse events were reported. Conclusions Oral upadacitinib combined with NB-UVB phototherapy demonstrated superior short-term efficacy compared with NB-UVB alone in patients with active non-segmental vitiligo, with an acceptable safety profile. These findings support this combination as a promising therapeutic strategy and warrant further validation in larger randomized controlled trials with longer follow-up.
Reference Key
openalex_W7221516782 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lu Lu, Jindi Feng, Lu Yang, Huimin He, Yubin Peng, Anqi Xie, Shiyu Zhang, Yuehua Liu, Tao Wang
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag437
URL
https://doi.org/10.1093/ced/llag437
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.